Clareo Health | Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients
Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Assistance Publique Hopitaux De Marseille
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Advanced NSCLC
One site of measureable disease by RECIST 1.1
Eligible for localized palliative radiotherapy of a bone lesion as per current national and international recommendations (part #1) or
Ability to tolerate hypo-fractionated radiotherapy of a tumoral lesion chosen according to the lower risk of radiation adverse event (lymph node \> subcutaneous \> liver \> bone \> lung) (part #2)
Received at least one prior line of therapy for incurable or metastatic NSCLC
Disease progression at study entry
You may not be if
Received systemic anticancer therapy within the previous 21 days
Human immunodeficiency virus (HIV), hepatitis B or C, or severe/uncontrolled infections or concurrent illness, unrelated to the tumor, requiring active therapy
Any condition requiring concurrent systemic immunosuppressive therapy
Known immunodeficiency disorders, either primary or acquired
Bone lesion with indication of surgery (part #1) ; especially in case of spinal compression.
Known leptomeningeal disease
Active malignancies within 12 months with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
Prior treatment with immune checkpoints inhibitors
Administration of a live, attenuated vaccine within 30 days prior to first dose of study drug
Long-term use of systemic corticosteroids (unless to a dose of 20mg of methylprednisolone)
